Ranibizumab API Manufacturers & Suppliers

Ranibizumab (CAS Number 347396-82-1) is a recombinant humanized IgG1 kappa monoclonal antibody fragment targeting human vascular endothelial growth factor A (VEGF-A). VEGF-A is a key mediator of pathological angiogenesis and vascular permeability involved in several ocular diseases. Ranibizumab is primarily indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD), as well as other ocular conditions characterized by abnormal blood vessel growth, including diabetic macular edema, diabetic retinopathy, macular edema following retinal vein occlusion, myopic choroidal neovascularization, and retinopathy of prematurity in certain jurisdictions.

Pharmacologically, ranibizumab binds with high affinity to multiple biologically active isoforms of VEGF-A, including VEGF165—the predominant isoform in ocular tissue responsible for neovascularization. By binding VEGF-A, ranibizumab blocks its interaction with VEGF receptors VEGFR1 and VEGFR2 on endothelial cells, thereby inhibiting downstream processes such as endothelial proliferation, vascular leakage, and new vessel formation. This mechanism reduces retinal edema and neovascularization, contributing to stabilization or improvement of vision in affected patients.

Ranibizumab is administered by intravitreal injection to maximize drug delivery to target retinal tissues while minimizing systemic exposure. Its molecular design as a smaller antibody fragment lacking the Fc region reduces intraocular inflammation risk relative to full-length antibodies. Pharmacokinetic data indicate that ranibizumab is cleared primarily via local ocular metabolism with minimal systemic accumulation.

Safety considerations include potential ocular adverse events related to intravitreal injection such as intraocular inflammation, increased intraocular pressure, and endophthalmitis. Systemic adverse events are infrequent but monitoring is warranted due to VEGF inhibition's theoretical impact on wound healing and thromboembolic risk.

Ranibizumab was first approved by the FDA in 2006 and the European Commission in 2007. It is marketed under the brands LUCENTIS and SUSVIMO. Several biosimilars, including BYOOVIZ, CIMERLI, RAIVISIO, and RANOPTO, have been approved in North America and Europe, providing additional sourcing options.

API procurement should focus on manufacturers adhering to stringent quality standards, including Good Manufacturing Practices (GMP), with robust control of critical quality attributes such as purity, binding affinity, and immunogenicity. Due to its recombinant protein nature, sourcing from validated suppliers with proven batch consistency and regulatory compliance is essential to ensure clinical efficacy and safety in finished pharmaceutical products.